A Double-Blind, Placebo-Controlled Study of Fluoxetine in Depressed Patients with Alzheimer's Disease

G.M. Petracca, E. Chemerinski, Sergio Starkstein

    Research output: Contribution to journalArticle

    116 Citations (Scopus)

    Abstract

    Objective: To examine the efficacy of fluoxetine in the treatment of depression in patients with probable Alzheimer's disease (AD). Methods: This double-blind, parallel-design study included a consecutive series of 41 AD subjects meeting DSM-IV criteria for major or minor depression who were randomized to receive fluoxetine (up to 40 mg/day) or identical-appearing placebo. All patients received biweekly evaluations consisting of the Hamilton Depression Scale (HAM-D) and the Clinical Global Impression as primary efficacy measures, and the Mini-Mental State Exam, Hamilton Rating Scale for Anxiety, and the Functional Independence Measure as secondary efficacy measures. Results: Complete remission of depression was found in 47% of subjects treated with fluoxetine and in 33% of subjects treated with placebo. Both the fluoxetine and the placebo groups showed a significant decline in HAM-D scores over time, but the magnitude of mood improvement was similar for both groups. Fluoxetine was well tolerated, and most side effects were mild. Conclusion: Fluoxetine treatment for depression in AD did not differ significantly from treatment with placebo. Our study also confirms the presence of a placebo effect in the treatment of depression in AD.
    Original languageEnglish
    Pages (from-to)233-240
    JournalInternational Psychogeriatrics
    Volume13
    Issue number2
    DOIs
    Publication statusPublished - 2001

    Fingerprint Dive into the research topics of 'A Double-Blind, Placebo-Controlled Study of Fluoxetine in Depressed Patients with Alzheimer's Disease'. Together they form a unique fingerprint.

    Cite this